Abstract:Objective To investigate the clinical efficacy of infliximab in the treatment of inflammatory bowel disease(IBD). Methods Thirty patients with Crohn's disease treated from February 2013 to September 2016 were randomly divided into observation group and control group(n=15, each). Infliximab maintenance treatment was given in control group, and combined regimen of infliximab and azathioprine was given in observation group. Before and 30 weeks after treatment, laboratory indexes including white blood cell count (WBC), C reactive protein (CRP), erythrocyte sedimentation rate (ESR), hemoglobin (HGB), albumin (ALB) and body mass index (BMI) were measured; Crohn's disease activity index (CDAI) method was used to assess the disease, and remission was defined as a CDAI score <150; simplified endoscopic score for Crohn's disease (SES-CD) was used to classify the severity of lesions under endoscopy and to evaluate the mucosal healing rate; deep-remission rate and adverse reaction incidence were calculated. Results After treatment, the levels of WBC, CRP and ESR significantly decreased, and the values of HGB, ALB and BMI significantly increased compared with those before treatment in both two groups (all P<0.01), and the values of CRP and ESR in observation group were significantly lower than those in control group(P<0.01). After treatment, CDAI score and SES-CD score were significantly lower than those before treatment in both two groups, however, there were no statistical differences in clinical remission rate(86.67% vs 80.00%), mucosal healing rate(60.00% vs 66.67%), deep-remission rate (66.67% vs 53.33%)and adverse reaction rate (26.67% vs 20.00%)(P>0.05). Conclusion Both single-drug therapy of infliximab and combined therapy of infliximab and immune inhibitor can effectively control the inflammatory response activities, maintain valid clinical remission, mucosal healing and deep-remission and has a good long-term curative effect in patients with Crohn's disease. Combined therapy has a better therapeutic effect in controlling inflammatory response.